Humanigen Elects Dr. Dale Chappell to Board of Directors
Monday, February 8th 2021 at 12:00pm UTC BURLINGAME, Calif.–(BUSINESS WIRE)– Humanigen, Inc. (NASDAQ:HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused…
Monday, February 8th 2021 at 12:00pm UTC BURLINGAME, Calif.–(BUSINESS WIRE)– Humanigen, Inc. (NASDAQ:HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused…
Thursday, January 7th 2021 at 3:00pm UTC Talton will lead the development of a new vision and strategy to advance…
Monday, February 8th 2021 at 2:30pm UTC First targeted stem cell factor receptor (anti-CD117) antibody evaluated as a conditioning agent…
Thursday, February 11th 2021 at 9:10pm UTC HAYWARD, Calif.–(BUSINESS WIRE)– Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to…
Thursday, February 11th 2021 at 12:30pm UTC BURLINGAME, Calif.–(BUSINESS WIRE)– Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company…
Monday, March 1st 2021 at 9:05pm UTC On track to complete the rolling tab-cel® BLA submission in Q3 2021 for…
Wednesday, February 17th 2021 at 11:45am UTC NEW YORK–(BUSINESS WIRE)– Pfizer Inc. (NYSE:PFE) today announced that the first participant has…
Monday, February 8th 2021 at 11:00am UTC PHILADELPHIA–(BUSINESS WIRE)– Seneca Therapeutics, Inc. (“STI”), a clinical-stage biopharmaceutical company dedicated to the…
Tuesday, February 9th 2021 at 2:00pm UTC Multi-site clinical study to evaluate BioBridge® as prophylactic treatment for at-risk patients UNION…
Tuesday, February 23rd 2021 at 10:00am UTC SYDNEY & LAGUNA HILLS, Calif.–(BUSINESS WIRE)– GenesisCare, a leading provider of integrated cancer…